We are live on ! Find out more
IMUX icon

Immunic

55 hedge funds and large institutions have $62.1M invested in Immunic in 2024 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 15 increasing their positions, 17 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0.18% less ownership

Funds ownership: 6.38%6.2% (-0.18%)

7% less funds holding

Funds holding: 5955 (-4)

12% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 17

18% less capital invested

Capital invested by funds: $75.7M → $62.1M (-$13.7M)

50% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 8

86% less call options, than puts

Call options by funds: $60K | Put options by funds: $419K

Holders
55
Holders Change
-4
Holders Change %
-6.78%
% of All Funds
0.79%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
4
Increased
15
Reduced
17
Closed
8
Calls
$60K
Puts
$419K
Net Calls
-$359K
Net Calls Change
-$8K

IMUX Hedge Fund Activity: Q2 2024 in Review

55 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Immunic (IMUX) for Q2 2024, worth a combined $62.1M — down 18% from $75.7M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of IMUX and 4 opened new positions — a net loss of 4 holders — while 17 trimmed existing stakes and 15 added.

The largest buyer was Vanguard Group, adding an estimated $430K. The largest seller was Ikarian Capital, cutting an estimated $1.39M.

  • 55 institutional investors held Immunic (IMUX) as of Q2 2024, down from 59 in Q1 2024.
  • Funds reported $62.1M of Immunic stock for Q2 2024, down 18% quarter-over-quarter.
  • 4 funds opened new Immunic positions in Q2 2024 and 8 closed out, a net change of -4 holders.
  • The largest Immunic buyer in Q2 2024 was Vanguard Group, an estimated $430K added.
  • The largest Immunic seller in Q2 2024 was Ikarian Capital, an estimated $1.39M sold.

Based on aggregated 13F filings for Q2 2024.